Bellevue Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,000	Closed	-$168K	–	161
2024 Q4	$168K	Hold	4,000	–	–	﹤0.01%	147
2024 Q3	$222K	Hold	4,000	–	–	﹤0.01%	144
2024 Q2	$164K	Buy	+4,000	New	+$164K	﹤0.01%	154
2022 Q3	–	Sell	-31,000	Closed	-$1.85M	–	183
2022 Q2	$1.85M	Buy	31,000 +5,300	+21%	+$316K	0.03%	131
2022 Q1	$1.87M	Buy	25,700 +4,700	+22%	+$341K	0.02%	137
2021 Q4	$1.77M	Sell	21,000 -6,900	-25%	-$580K	0.02%	148
2021 Q3	$2.52M	Buy	27,900 +6,500	+30%	+$586K	0.03%	143
2021 Q2	$2.04M	Sell	21,400 -19,600	-48%	-$1.87M	0.02%	142
2021 Q1	$4.67M	Hold	41,000	–	–	0.05%	132
2020 Q4	$5.68M	Hold	41,000	–	–	0.07%	123
2020 Q3	$3.37M	Buy	41,000 +17,000	+71%	+$1.4M	0.05%	133
2020 Q2	$1.88M	Buy	24,000 +2,500	+12%	+$196K	0.03%	137
2020 Q1	$955K	Buy	+21,500	New	+$955K	0.02%	142
2019 Q3	–	Sell	-22,800	Closed	-$1.45M	–	218
2019 Q2	$1.45M	Sell	22,800 -7,000	-23%	-$445K	0.02%	137
2019 Q1	$2.07M	Buy	29,800 +7,600	+34%	+$527K	0.11%	107
2018 Q4	$965K	Sell	22,200 -9,650	-30%	-$419K	0.06%	116
2018 Q3	$2.43M	Sell	31,850 -7,300	-19%	-$557K	0.15%	100
2018 Q2	$3.01M	Sell	39,150 -1,150	-3%	-$88.4K	0.26%	75
2018 Q1	$2.06M	Sell	40,300 -600	-1%	-$30.6K	0.2%	78
2017 Q4	$1.9M	Sell	40,900 -1,100	-3%	-$51K	0.2%	80
2017 Q3	$2.24M	Hold	42,000	–	–	0.23%	78
2017 Q2	$1.62M	Hold	42,000	–	–	0.19%	89
2017 Q1	$2.85M	Sell	42,000 -1,000	-2%	-$67.8K	0.38%	66
2016 Q4	$3.02M	Hold	43,000	–	–	0.62%	46
2016 Q3	$3.05M	Buy	43,000 +15,000	+54%	+$1.06M	0.55%	54
2016 Q2	$1.37M	Buy	28,000 +18,000	+180%	+$880K	0.26%	88
2016 Q1	$633K	Buy	+10,000	New	+$633K	0.11%	106